Found: 13
Select item for more details and to access through your institution.
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study.
- Published in:
- Hepatology Research, 2021, v. 51, n. 12, p. 1229, doi. 10.1111/hepr.13718
- By:
- Publication type:
- Article
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
- Published in:
- Hepatology Research, 2021, v. 51, n. 7, p. 796, doi. 10.1111/hepr.13669
- By:
- Publication type:
- Article
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 2, p. 215, doi. 10.1159/000534127
- By:
- Publication type:
- Article
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.
- Published in:
- Liver International, 2024, v. 44, n. 5, p. 1108, doi. 10.1111/liv.15885
- By:
- Publication type:
- Article
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
- Published in:
- Liver International, 2021, v. 41, n. 6, p. 1389, doi. 10.1111/liv.14817
- By:
- Publication type:
- Article
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231171574
- By:
- Publication type:
- Article
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 13, p. 5325, doi. 10.1245/s10434-020-08515-5
- By:
- Publication type:
- Article
Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
- Published in:
- Current Oncology, 2023, v. 30, n. 6, p. 5515, doi. 10.3390/curroncol30060417
- By:
- Publication type:
- Article
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 9379, doi. 10.2147/CMAR.S330195
- By:
- Publication type:
- Article
Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 01, doi. 10.3389/fonc.2022.989713
- By:
- Publication type:
- Article
What do cancer patients experience of the simultaneous care clinic? Results of a cross‐sectional study on patient care satisfaction.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.7000
- By:
- Publication type:
- Article
Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 3, p. 812, doi. 10.3390/jcm11030812
- By:
- Publication type:
- Article
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 10, p. 1726, doi. 10.3390/jpm12101726
- By:
- Publication type:
- Article